Bluejay Diagnostics Inc. has announced a $4.5 million private placement priced at-the-market under Nasdaq rules. The company has entered into definitive agreements for the sale of 2,250,000 shares of common stock (or pre-funded warrants) and Series F warrants to purchase up to 4,500,000 shares of common stock, at a purchase price of $2.00 per share and accompanying warrant. The Series F warrants have an exercise price of $1.75 per share, are exercisable immediately, and will expire 5.5 years from issuance. Rodman and Renshaw LLC is acting as the exclusive placement agent for the offering. Bluejay Diagnostics intends to use the net proceeds to support FDA approval efforts, research and development activities, and general working capital.